1. Home
  2. DRUG

as of 09-15-2026 3:48pm EST

$60.45
+$0.23
+0.38%
Stocks Health Care Pharmaceuticals and Biotechnology Nasdaq

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Founded: 2019 Country:
United States
United States
Employees: N/A City: N/A
Market Cap: 778.4M IPO Year: 2020
Target Price: $129.25 AVG Volume (30 days): 76.2K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $44.25 - $123.75 Next Earning Date: 05-15-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: